Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting.

ABSTRACT:

Background

Anlotinib is a novel tyrosine kinase inhibitor with promising anti-tumor activity in patients with advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the efficacy and safety of anlotinib maintenance therapy in patients with advanced NSCLC in real-world situation.

Methods

We conducted a retrospective study on the patients with stage IIIb or IV NSCLC who visited our hospital between December 2016 and April 2020. They achieved an objective response or stable disease after first- or second- line treatment and then received switch maintenance therapy with anlotinib. Data were collected using automated data mining technology from electronic health records. Patients' demographic and clinical characteristics, median progression-free surviva

SUBMITTER: Li J 

PROVIDER: S-EPMC9282872 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature